OverweightNCT07513610
The Effects of Quinoa and Buckwheat on Weight Management and Gut Microbiome
A study testing quinoa, Buckwheat and Rice in people with Overweight and Obesity, run by Hacettepe University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to compare the effects of quinoa, buckwheat, rice, and bulgur consumption on dietary intake, anthropometric measurements, glycemic response, lipid profile, inflammatory markers, blood pressure, and intestinal microbiome in people with overweight and obesity. Read more about this study
- Who is it for?
- Ages 25 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight, Obesity
- What is being tested?
- quinoa, Buckwheat and Rice
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 148 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 24 Jan 2024to 8 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Aged between 25 and 45
- Healthy People
- Having a body mass index between 25 and 35 kg/m²
Who cannot join
- To have a diagnosis of chronic and/or psychiatric illness
- To have diagnosis of celiac disease
- To be using antibiotics
- To be using medication and/or nutritional supplements that can affect body weight
- To be using medication and/or nutritional supplements that can affect glycemic response
- To be using medication and/or nutritional supplements that can affect lipid profile
Show all 16Show fewer
- To use medication and/or nutritional supplements that can affect intestinal microbiota composition (such as antibiotics, probiotics, prebiotics) in the last three months
- To have food allergies and/or food intolerances
- To be a professional athlete
- To be pregnant or breastfeeding
- To be in postmenopausal period
- To have followed a specific diet aimed at reducing body weight in the last 6 months
- To regularly consume quinoa or buckwheat in the diet
- To be unable to continue with weekly interviews
- To show less than 80% compliance with the diet
- To not give consent for the research
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effects of Dietary Quinoa and Buckwheat Consumption on Weight Management and Gut Microbiome
This study aims to compare the effects of quinoa, buckwheat, rice, and bulgur consumption on dietary intake, anthropometric measurements, glycemic response, lipid profile, inflammatory markers, blood pressure, and intestinal microbiome in people with overweight and obesity. The primary hypotheses of the studies were given as follows:
Hypothesis 1:
Read more
H1: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet provides weight loss.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not provide body weight loss.
Hypothesis 2:
H2: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet affects glycemic response.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not affect glycemic response.
Hypothesis 3:
H3: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet affects the blood lipid profile.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not affect the blood lipid profile.
Hypothesis 4:
H4: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet changes the composition of the gut microbiome.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not change the composition of the gut microbiome.
Hypothesis 5:
H5: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet increases alpha diversity in the intestinal microbiome.
HO: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not increase alpha diversity in the intestinal microbiome.
Hypothesis 6:
H6: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet increases beta diversity in the intestinal microbiome.
HO: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not increase beta diversity in the intestinal microbiome.
Read the detailed description
The study is designed as a randomized, controlled clinical trial in which participants will be allocated into four groups (quinoa, buckwheat, bulgur, and rice groups), each consisting of 31 or 32 pre-obese/obese adults. During the 28-day intervention period, participants' diets were supplemented with 40 g/day of quinoa (Chenopodium quinoa), buckwheat (Fagopyrum esculentum), bulgur wheat (Triticum durum), or rice (Oryza sativa).
Weekly face-to-face visits were conducted throughout the intervention to collect anthropometric measurements and dietary intake records and to assess intervention compliance and physical activity level.
At baseline and at the end of the intervention, physical examinations were performed, blood and fecal samples were collected, blood pressure was measured, and anthropometric measurements and dietary intake records were evaluated. Serum levels of triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, glucose, insulin, fructosamine, adiponectin, C-reactive protein, malondialdehyde, uric acid, lipopolysaccharide, TNF-alpha, IL-6, zonulin, and lipopolysaccharides will be analyzed. Additionally, fecal samples will be analyzed to reveal any possible changes in gut microbiome. Given the scarcity of clinical studies in this field, this study is expected to contribute to addressing the lack of high-level clinical evidence in the literature.
- Conditions
- Overweight, Obesity
- Being tested
- quinoa, Buckwheat, Rice, Bulgur wheat
- Keywords
- quinoa, buckwheat, pseudocereals, body weight, obesity, cardiometabolic health, gut microbiome
- Medical subject headings
- Overweight, Obesity, Body Weight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
quinoaDietary supplement
Participants consumed 40 g/d red quinoa during 4 weeks. Participants were instructed to consume red quinoa by boiling it without any other ingredients.
BuckwheatDietary supplement
Participants consumed 40 g/d of buckwheat during 4 weeks. Participants were instructed to consume buckwheat by boiling it without any other ingredients.
RiceDietary supplement
Participants consumed 40 g/d rice during 4 weeks. Participants were instructed to consume rice by boiling it without any other ingredients.
Bulgur wheatDietary supplement
Participants consumed 40 g/d of bulgur wheat during 4 weeks. Participants were instructed to consume bulgur wheat by boiling it without any other ingredients.
| Study group | Role | What they receive |
|---|---|---|
| Quinoa Group | Experimental | Participants' diets were supplemented with 40 g of red quinoa per day for 4 weeks. Participants were instructed to boil red quinoa without adding any other ingredients. Receives: Dietary Supplement: quinoa |
| buckwheat group | Experimental | Participants' diets were supplemented with 40 g of buckwheat per day for 4 weeks. Participants were instructed to boil buckwheat without adding any other ingredients. Receives: Dietary Supplement: Buckwheat |
| Rice group | Active comparator | Participants' diets were supplemented with 40 g of rice per day for 4 weeks. Participants were instructed to boil rice without adding any other ingredients. Receives: Dietary Supplement: Rice |
| Bulgur Wheat Group | Active comparator | Participants' diets were supplemented with 40 g of bulgur wheat per day for 4 weeks. Participants were instructed to boil bulgur wheat without adding any other ingredients. Receives: Dietary Supplement: Bulgur wheat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight loss
Body weight and body composition will be measured with a bioelectrical impedance analysis-based body analyzer.
Measured: From the beginning of the study to the end of the 4-week intervention period (up to 4 weeks), with measurements taken once a week.
Blood lipid levels (mg/dL)
Total cholesterol (mg/dL), LDL cholesterol (mg/dL), HDL cholesterol (mg/dL), and triglyceride levels (mg/dL) will be analyzed in blood serum.
Measured: At the beginning of the study and at the end of 4-weeks intervention period
Blood glucose levels (mg/dL) during a 75 g oral glucose tolerance test (OGTT) procedure
Fasting glucose levels (0.minutes, before the 75 g oral glucose load) and postprandial glucose levels (30, 60, 90, and 120 minutes following the 75 g oral glucose load) will be assessed in blood serum during the 75 g oral glucose tolerance test procedure.
Measured: At the beginning of the study and at the end of the 4-week intervention period, during each assessment, blood samples will be collected at 0. Minutes (fasting) and 30, 60, 90, and 120 minutes following the 75 g oral glucose load.
Blood insulin levels (µIU/mL) during a 75 g oral glucose tolerance test (OGTT) procedure
Fasting insulin levels (0.minutes, before the 75 g oral glucose load) and postprandial insulin levels (30, 60, 90, and 120 minutes following the 75 g oral glucose load) will be assessed in blood serum during the 75 g oral glucose tolerance test procedure.
Measured: At the beginning of the study and at the end of the 4-week intervention period, during each assessment, blood samples will be collected at 0. Minutes (fasting) and 30, 60, 90, and 120 minutes following the 75 g oral glucose load.
Changes in gut microbiome composition
Changes in gut microbiome composition will be assessed in fecal samples
Measured: At the beginning of the study and at the end of 4-week intervention period
Changes in Alpha Diversity
Changes in alpha diversity in intestinal microbiota will be evaluated.
Measured: At the beginning of the study and at the end of 4-week intervention period
Changes in Beta Diversity
Changes in Beta Diversity in intestinal microbiota will be evaluated
Measured: At the beginning of the study and at the end of 4-week intervention period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start24 Jan 2024
- Primary completion17 Jan 2025
- Study completion8 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for OverweightStudies of the same condition, open and under way.
- More trials run by Hacettepe UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 148 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hacettepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ZEHRA BUYUKTUNCER, Hacettepe University
- Investigators
- Zehra Buyuktuncer, Prof. Dr., Study director, Hacettepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07513610
- Sponsor's protocol ID
- KA-19102
- Other IDs
- 20780
- Status last verified
- Mar 2026
- First submitted
- 14 Mar 2026
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Li L, Houghton D, Lietz G, Watson A, Stewart CJ, Bal W, Seal CJ. Impact of Daily Consumption of Whole-Grain Quinoa-Enriched Bread on Gut Microbiome in Males. Nutrients. 2022 Nov 18;14(22):4888. doi: 10.3390/nu14224888.
PubMed 36432574Canaviri-Paz P, Oscarsson E, Kjellstrom A, Olsson H, Jois C, Hakansson A. Effects on Microbiota Composition after Consumption of Quinoa Beverage Fermented by a Novel Xylose-Metabolizing L. plantarum Strain. Nutrients. 2021 Sep 23;13(10):3318. doi: 10.3390/nu13103318.
PubMed 34684319Neacsu M, Sayegh M, Vaughan NJ, Duncan GJ, Cantlay L, Anderson S, Henderson D, Fyfe C, Farquharson F, Saibu S, Horgan G, Louis P, Johnstone AM, Russell WR. Fava bean and buckwheat are sustainable food sources which support satiety and beneficially modulate several biomarkers, bacteria and metabolites associated with human health. Eur J Nutr. 2025 Jun 7;64(5):211. doi: 10.1007/s00394-025-03726-6.
PubMed 40481954Espada MV, De la Cruz CR, Jeri C, Garcia-Tejedor A, Laparra JM. Chenopodium Quinoa's Ingredients Contribute to the Gut Microbiota's Metabolic Adaptations on Carbohydrate Metabolism. Plant Foods Hum Nutr. 2024 Dec 21;80(1):18. doi: 10.1007/s11130-024-01253-z.
PubMed 39708162Li L, Lietz G, Bal W, Watson A, Morfey B, Seal C. Effects of Quinoa (Chenopodium quinoa Willd.) Consumption on Markers of CVD Risk. Nutrients. 2018 Jun 16;10(6):777. doi: 10.3390/nu10060777.
PubMed 29914146Navarro-Perez D, Radcliffe J, Tierney A, Jois M. Quinoa Seed Lowers Serum Triglycerides in Overweight and Obese Subjects: A Dose-Response Randomized Controlled Clinical Trial. Curr Dev Nutr. 2017 Aug 24;1(9):e001321. doi: 10.3945/cdn.117.001321. eCollection 2017 Sep.
PubMed 29955719De Carvalho FG, Ovidio PP, Padovan GJ, Jordao Junior AA, Marchini JS, Navarro AM. Metabolic parameters of postmenopausal women after quinoa or corn flakes intake--a prospective and double-blind study. Int J Food Sci Nutr. 2014 May;65(3):380-5. doi: 10.3109/09637486.2013.866637. Epub 2013 Dec 17.
PubMed 24344670Marak NR, Das P, Das Purkayastha M, Baruah LD. Effect of quinoa (Chenopodium quinoa W.) flour supplementation in breads on the lipid profile and glycemic index: an in vivo study. Front Nutr. 2024 Mar 26;11:1341539. doi: 10.3389/fnut.2024.1341539. eCollection 2024.
PubMed 38595791Pourshahidi LK, Caballero E, Osses A, Hyland BW, Ternan NG, Gill CIR. Modest improvement in CVD risk markers in older adults following quinoa (Chenopodium quinoa Willd.) consumption: a randomized-controlled crossover study with a novel food product. Eur J Nutr. 2020 Oct;59(7):3313-3323. doi: 10.1007/s00394-019-02169-0. Epub 2020 Jan 9.
PubMed 31919583
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Dietary Quinoa and Buckwheat Consumption on Weight Management and Gut Microbiome
- ClinicalTrials.gov ID
- NCT07513610
- Acronym / sponsor ID
- KA-19102
- Conditions
- Overweight, Obesity
- Keywords
- quinoa, buckwheat, pseudocereals, body weight, obesity, cardiometabolic health, gut microbiome
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 148 participants (actual)
- Lead sponsor
- Hacettepe UniversityUniversity, hospital or other
- Study start
- 24 Jan 2024 (actual)
- Primary completion
- 17 Jan 2025 (actual)
- Study completion
- 8 Feb 2025 (actual)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the effects of quinoa, buckwheat, rice, and bulgur consumption on dietary intake, anthropometric measurements, glycemic response, lipid profile, inflammatory markers, blood pressure, and intestinal microbiome in people with overweight and obesity. The primary hypotheses of the studies were given as follows:
Hypothesis 1:
H1: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet provides weight loss.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not provide body weight loss.
Hypothesis 2:
H2: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet affects glycemic response.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not affect glycemic response.
Hypothesis 3:
H3: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet affects the blood lipid profile.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not affect the blood lipid profile.
Hypothesis 4:
H4: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet changes the composition of the gut microbiome.
H0: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not change the composition of the gut microbiome.
Hypothesis 5:
H5: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet increases alpha diversity in the intestinal microbiome.
HO: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not increase alpha diversity in the intestinal microbiome.
Hypothesis 6:
H6: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet increases beta diversity in the intestinal microbiome.
HO: In people with overweight and obesity, the addition of quinoa and buckwheat to the diet does not increase beta diversity in the intestinal microbiome.
Detailed description
The study is designed as a randomized, controlled clinical trial in which participants will be allocated into four groups (quinoa, buckwheat, bulgur, and rice groups), each consisting of 31 or 32 pre-obese/obese adults. During the 28-day intervention period, participants' diets were supplemented with 40 g/day of quinoa (Chenopodium quinoa), buckwheat (Fagopyrum esculentum), bulgur wheat (Triticum durum), or rice (Oryza sativa).
Weekly face-to-face visits were conducted throughout the intervention to collect anthropometric measurements and dietary intake records and to assess intervention compliance and physical activity level.
At baseline and at the end of the intervention, physical examinations were performed, blood and fecal samples were collected, blood pressure was measured, and anthropometric measurements and dietary intake records were evaluated. Serum levels of triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, glucose, insulin, fructosamine, adiponectin, C-reactive protein, malondialdehyde, uric acid, lipopolysaccharide, TNF-alpha, IL-6, zonulin, and lipopolysaccharides will be analyzed. Additionally, fecal samples will be analyzed to reveal any possible changes in gut microbiome. Given the scarcity of clinical studies in this field, this study is expected to contribute to addressing the lack of high-level clinical evidence in the literature.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Quinoa Group | Experimental | Dietary Supplement: quinoaParticipants' diets were supplemented with 40 g of red quinoa per day for 4 weeks. Participants were instructed to boil red quinoa without adding any other ingredients. |
| buckwheat group | Experimental | Dietary Supplement: BuckwheatParticipants' diets were supplemented with 40 g of buckwheat per day for 4 weeks. Participants were instructed to boil buckwheat without adding any other ingredients. |
| Rice group | Active comparator | Dietary Supplement: RiceParticipants' diets were supplemented with 40 g of rice per day for 4 weeks. Participants were instructed to boil rice without adding any other ingredients. |
| Bulgur Wheat Group | Active comparator | Dietary Supplement: Bulgur wheatParticipants' diets were supplemented with 40 g of bulgur wheat per day for 4 weeks. Participants were instructed to boil bulgur wheat without adding any other ingredients. |
Who may qualify
- Ages
- 25 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Aged between 25 and 45
- Healthy People
- Having a body mass index between 25 and 35 kg/m²
Key exclusion criteria (16 listed)
- To have a diagnosis of chronic and/or psychiatric illness
- To have diagnosis of celiac disease
- To be using antibiotics
- To be using medication and/or nutritional supplements that can affect body weight
- To be using medication and/or nutritional supplements that can affect glycemic response
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| quinoaParticipants consumed 40 g/d red quinoa during 4 weeks. Participants were instructed to consume red quinoa by boiling it without any other ingredients. | Dietary supplement | Quinoa Group |
| BuckwheatParticipants consumed 40 g/d of buckwheat during 4 weeks. Participants were instructed to consume buckwheat by boiling it without any other ingredients. | Dietary supplement | buckwheat group |
| RiceParticipants consumed 40 g/d rice during 4 weeks. Participants were instructed to consume rice by boiling it without any other ingredients. | Dietary supplement | Rice group |
| Bulgur wheatParticipants consumed 40 g/d of bulgur wheat during 4 weeks. Participants were instructed to consume bulgur wheat by boiling it without any other ingredients. | Dietary supplement | Bulgur Wheat Group |
Primary outcome
Weight loss
Time frame: From the beginning of the study to the end of the 4-week intervention period (up to 4 weeks), with measurements taken once a week.
Body weight and body composition will be measured with a bioelectrical impedance analysis-based body analyzer.
Blood lipid levels (mg/dL)
Time frame: At the beginning of the study and at the end of 4-weeks intervention period
Total cholesterol (mg/dL), LDL cholesterol (mg/dL), HDL cholesterol (mg/dL), and triglyceride levels (mg/dL) will be analyzed in blood serum.
Blood glucose levels (mg/dL) during a 75 g oral glucose tolerance test (OGTT) procedure
Time frame: At the beginning of the study and at the end of the 4-week intervention period, during each assessment, blood samples will be collected at 0. Minutes (fasting) and 30, 60, 90, and 120 minutes following the 75 g oral glucose load.
Fasting glucose levels (0.minutes, before the 75 g oral glucose load) and postprandial glucose levels (30, 60, 90, and 120 minutes following the 75 g oral glucose load) will be assessed in blood serum during the 75 g oral glucose tolerance test procedure.
Blood insulin levels (µIU/mL) during a 75 g oral glucose tolerance test (OGTT) procedure
Time frame: At the beginning of the study and at the end of the 4-week intervention period, during each assessment, blood samples will be collected at 0. Minutes (fasting) and 30, 60, 90, and 120 minutes following the 75 g oral glucose load.
Fasting insulin levels (0.minutes, before the 75 g oral glucose load) and postprandial insulin levels (30, 60, 90, and 120 minutes following the 75 g oral glucose load) will be assessed in blood serum during the 75 g oral glucose tolerance test procedure.
Changes in gut microbiome composition
Time frame: At the beginning of the study and at the end of 4-week intervention period
Changes in gut microbiome composition will be assessed in fecal samples
Changes in Alpha Diversity
Time frame: At the beginning of the study and at the end of 4-week intervention period
Changes in alpha diversity in intestinal microbiota will be evaluated.
Changes in Beta Diversity
Time frame: At the beginning of the study and at the end of 4-week intervention period
Changes in Beta Diversity in intestinal microbiota will be evaluated
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Background: PubMed 36432574Li L, Houghton D, Lietz G, Watson A, Stewart CJ, Bal W, Seal CJ. Impact of Daily Consumption of Whole-Grain Quinoa-Enriched Bread on Gut Microbiome in Males. Nutrients. 2022 Nov 18;14(22):4888. doi: 10.3390/nu14224888.
- Background: PubMed 34684319Canaviri-Paz P, Oscarsson E, Kjellstrom A, Olsson H, Jois C, Hakansson A. Effects on Microbiota Composition after Consumption of Quinoa Beverage Fermented by a Novel Xylose-Metabolizing L. plantarum Strain. Nutrients. 2021 Sep 23;13(10):3318. doi: 10.3390/nu13103318.
- Background: PubMed 40481954Neacsu M, Sayegh M, Vaughan NJ, Duncan GJ, Cantlay L, Anderson S, Henderson D, Fyfe C, Farquharson F, Saibu S, Horgan G, Louis P, Johnstone AM, Russell WR. Fava bean and buckwheat are sustainable food sources which support satiety and beneficially modulate several biomarkers, bacteria and metabolites associated with human health. Eur J Nutr. 2025 Jun 7;64(5):211. doi: 10.1007/s00394-025-03726-6.
- Background: PubMed 39708162Espada MV, De la Cruz CR, Jeri C, Garcia-Tejedor A, Laparra JM. Chenopodium Quinoa's Ingredients Contribute to the Gut Microbiota's Metabolic Adaptations on Carbohydrate Metabolism. Plant Foods Hum Nutr. 2024 Dec 21;80(1):18. doi: 10.1007/s11130-024-01253-z.
- Background: PubMed 29914146Li L, Lietz G, Bal W, Watson A, Morfey B, Seal C. Effects of Quinoa (Chenopodium quinoa Willd.) Consumption on Markers of CVD Risk. Nutrients. 2018 Jun 16;10(6):777. doi: 10.3390/nu10060777.
- Background: PubMed 29955719Navarro-Perez D, Radcliffe J, Tierney A, Jois M. Quinoa Seed Lowers Serum Triglycerides in Overweight and Obese Subjects: A Dose-Response Randomized Controlled Clinical Trial. Curr Dev Nutr. 2017 Aug 24;1(9):e001321. doi: 10.3945/cdn.117.001321. eCollection 2017 Sep.
- Background: PubMed 24344670De Carvalho FG, Ovidio PP, Padovan GJ, Jordao Junior AA, Marchini JS, Navarro AM. Metabolic parameters of postmenopausal women after quinoa or corn flakes intake--a prospective and double-blind study. Int J Food Sci Nutr. 2014 May;65(3):380-5. doi: 10.3109/09637486.2013.866637. Epub 2013 Dec 17.
- Background: PubMed 38595791Marak NR, Das P, Das Purkayastha M, Baruah LD. Effect of quinoa (Chenopodium quinoa W.) flour supplementation in breads on the lipid profile and glycemic index: an in vivo study. Front Nutr. 2024 Mar 26;11:1341539. doi: 10.3389/fnut.2024.1341539. eCollection 2024.
- Background: PubMed 31919583Pourshahidi LK, Caballero E, Osses A, Hyland BW, Ternan NG, Gill CIR. Modest improvement in CVD risk markers in older adults following quinoa (Chenopodium quinoa Willd.) consumption: a randomized-controlled crossover study with a novel food product. Eur J Nutr. 2020 Oct;59(7):3313-3323. doi: 10.1007/s00394-019-02169-0. Epub 2020 Jan 9.
- Individual participant dataSharing planned: No
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zehra Buyuktuncer, Prof. Dr. study director
Hacettepe University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing quinoa, Buckwheat and Rice in people with Overweight and Obesity, run by Hacettepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight loss (time frame: From the beginning of the study to the end of the 4-week intervention period (up to 4 weeks), with measurements taken once a week.). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07513610, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.